The Real Risks of Alzheimer’s
Preclinical AD does not always lead to dementia
William Aryitey |
The brain – both in terms of structure and function– is highly complex. And though decades of research have taught us much about the body’s control center, there is still a whole world of knowledge to uncover, especially when it comes to age-related neurological conditions, such as dementia. Alzheimer’s disease (AD) – the most common form of dementia – has become an increasingly significant issue as life expectancy in the developed world has risen. But the more we understand about the disease and its pathology, the closer we edge to a viable treatment.
A study by researchers at the University of California, Los Angeles (UCLA) has estimated the lifetime risk of AD for people with preclinical disease and found that they have a low likelihood of developing overt disease in their lifetime (1). To learn more about the findings and their clinical significance, we spoke with Ron Brookmeyer, first author of the study and Professor of Biostatistics at UCLA Fielding School of Public Health.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine